LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Masahiro Tsuboi, Yi‐Long Wu, C Grohé, Thomas John, M. Majem Tarruella, J. Wang, T. Kato, J.W. Goldman, S-W. Kim, Chong‐Jen Yu, Hữu Vĩnh Vũ, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Frances A. Shepherd, Damien Urban, Marta Stachowiak, Ana Bolanos, X. Huang, R.S. Herbst
Topics & Concepts
OsimertinibMedicineInternal medicineT790MClinical endpointAdjuvantOncologyLung cancerStage (stratigraphy)non-small cell lung cancer (NSCLC)CancerErlotinibClinical trialGefitinibEpidermal growth factor receptorBiologyPaleontologyA549 cellLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies